首页 > 最新文献

Sarcoidosis, Vasculitis, and Diffuse Lung Diseases最新文献

英文 中文
BALF and BLOOD NK- cells in different stages of pulmonary sarcoidosis. 肺结节病不同分期BALF和NK细胞的变化。
IF 1.6 4区 医学 Q3 Medicine Pub Date : 2022-01-01 Epub Date: 2022-01-13 DOI: 10.36141/svdld.v38i4.10810
Katerina Manika, Kalliopi Domvri, George Kyriazis, Theodoros Kontakiotis, Despina Papakosta

Background and objective: Data on natural killer (NK)- and natural killer T (NKT)- like cells in the immunopathogenesis of sarcoidosis remain limited. The aim was to assess NK- and NKT-like cells across different stages in bronchoalveolar lavage (BALF) versus peripheral blood (PB) in comparison to controls.

Methods: Forty four patients (32 women and 12 men, mean age 46.6±14.4 years) with biopsy-proven sarcoidosis and 10 healthy individuals (6 women, 4 men mean age 52.6±19.1 years) were submitted to BALF. Total cells and cell differentials were counted, while CD45+, CD3+, CD4+, CD8+, CD19+, CD3-CD16/56 (NK cells) and CD3+CD16/56+ (NKT-like cells) were determined by dual flow cytometry in BALF and PB.

Results: A significantly lower percentage of both NK and NKT-like cells was observed in BALF of controls and sarcoid patients (SP) compared to PB. Both BALF NK and NKT-cell counts were significantly higher in SP than in controls (NK: p=0.046, NKT-like: p=0.012) In addition BALF NK cell percentage differed among sarcoidosis stages (p=0.005). In PB NK-cell count was lower in sarcoidosis patients but the difference did not reach statistical significance. Also, in sarcoid patients' BALF NK-cell percentage negatively correlated with lymphocyte percentage (r=-0.962, p<0.001).

Conclusions: The increased count of BALF NK and NKT-like cells in sarcoidosis compared to controls along with the increase of NK cells with stage progression are in line with a growing number of investigations suggesting the involvement of NK- and NKT-like cells in the pathogenesis of sarcoidosis.

背景和目的:关于自然杀伤细胞(NK)和自然杀伤T细胞(NKT)样细胞在结节病免疫发病机制中的作用的数据仍然有限。目的是评估NK-和nkt样细胞在支气管肺泡灌洗(BALF)和外周血(PB)的不同阶段与对照组相比。方法:对44例经活检证实的结节病患者(女32例,男12例,平均年龄46.6±14.4岁)和10例健康者(女6例,男4例,平均年龄52.6±19.1岁)进行BALF。采用双流式细胞术检测BALF和PB细胞的CD45+、CD3+、CD4+、CD8+、CD19+、CD3-CD16/56 (NK细胞)和CD3+CD16/56+ (nkt样细胞)。结果:与PB相比,对照组和肉瘤患者(SP)的BALF中NK细胞和nkt样细胞的百分比均显著降低。SP组BALF NK和nkt细胞计数均显著高于对照组(NK: p=0.046, nkt样:p=0.012),不同结节病分期BALF NK细胞百分比差异显著(p=0.005)。结节病患者外周血nk细胞计数较低,但差异无统计学意义。结论:结节病中BALF NK细胞和nkt样细胞的数量随着分期的进展而增加,与对照组相比,BALF NK细胞和nkt样细胞的数量增加,这与越来越多的研究结果一致,表明NK细胞和nkt样细胞参与结节病的发病机制。
{"title":"BALF and BLOOD NK- cells in different stages of pulmonary sarcoidosis.","authors":"Katerina Manika,&nbsp;Kalliopi Domvri,&nbsp;George Kyriazis,&nbsp;Theodoros Kontakiotis,&nbsp;Despina Papakosta","doi":"10.36141/svdld.v38i4.10810","DOIUrl":"https://doi.org/10.36141/svdld.v38i4.10810","url":null,"abstract":"<p><strong>Background and objective: </strong>Data on natural killer (NK)- and natural killer T (NKT)- like cells in the immunopathogenesis of sarcoidosis remain limited. The aim was to assess NK- and NKT-like cells across different stages in bronchoalveolar lavage (BALF) versus peripheral blood (PB) in comparison to controls.</p><p><strong>Methods: </strong>Forty four patients (32 women and 12 men, mean age 46.6±14.4 years) with biopsy-proven sarcoidosis and 10 healthy individuals (6 women, 4 men mean age 52.6±19.1 years) were submitted to BALF. Total cells and cell differentials were counted, while CD45+, CD3+, CD4+, CD8+, CD19+, CD3-CD16/56 (NK cells) and CD3+CD16/56+ (NKT-like cells) were determined by dual flow cytometry in BALF and PB.</p><p><strong>Results: </strong>A significantly lower percentage of both NK and NKT-like cells was observed in BALF of controls and sarcoid patients (SP) compared to PB. Both BALF NK and NKT-cell counts were significantly higher in SP than in controls (NK: p=0.046, NKT-like: p=0.012) In addition BALF NK cell percentage differed among sarcoidosis stages (p=0.005). In PB NK-cell count was lower in sarcoidosis patients but the difference did not reach statistical significance. Also, in sarcoid patients' BALF NK-cell percentage negatively correlated with lymphocyte percentage (r=-0.962, p<0.001).</p><p><strong>Conclusions: </strong>The increased count of BALF NK and NKT-like cells in sarcoidosis compared to controls along with the increase of NK cells with stage progression are in line with a growing number of investigations suggesting the involvement of NK- and NKT-like cells in the pathogenesis of sarcoidosis.</p>","PeriodicalId":21394,"journal":{"name":"Sarcoidosis, Vasculitis, and Diffuse Lung Diseases","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c1/27/SVDLD-38-39.PMC8787376.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39747945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Bronchoscopic Probe-Based Confocal Laser Endomicroscopy to Diagnose Diffuse Parenchymal Lung Diseases. 基于探针的支气管镜共聚焦激光内镜诊断弥漫性肺实质疾病。
IF 1.6 4区 医学 Q3 Medicine Pub Date : 2022-01-01 Epub Date: 2022-06-29 DOI: 10.36141/svdld.v39i2.11280
Edith Silbernagel, Elvira Stacher-Priehse, Julien Dinkel, Herbert Stepp, Wolfgang Gesierich, Michael Lindner, Juergen Behr, Frank Reichenberger
Background Diagnosis of diffuse parenchymal lung disease (DPLD) is based on clinical evaluation, radiological imaging and histology. However, additional techniques are warranted to improve diagnosis. Aims and objective Probe based confocal laser endomicroscopy (pCLE) allows real time in vivo visualisation of the alveolar compartment during bronchoscopy based on autofluorescence of elastic fibres. We used pCLE (Cellvizio®, Mauna Kea Technology. Inc, Paris, France) to characterise alveolar patterns in patients with different types of DPLD. Methods In this pilot study we included 42 therapy naive patients (13 female, age 72.6 +/- 2.3 years), who underwent bronchoscopy for workup of DPLD. pCLE images were obtained during rigid bronchoscopy in affected lung segments according to HR-CT scan, followed by cryobiopsies in the identical area. Diagnoses were made by a multidisciplinary panel. The description of pCLE patterns was based on the degree of distortion of the hexagonal alveolar pattern, the density of alveolar structures, the presence of consolidations or loaded alveolar macrophages (AM). The assessment was performed by 2 investigators blinded for the final diagnosis. Results The normal lung showed a typical alveolar loop pattern. In amiodarone lung disease loaded AM were predominant. COP showed characteristic focal consolidations. IPF was characterized by significant distortion and destruction, NSIP showed significant increase in density, and chronic HP presented with consolidations, mild distortion and density. Conclusion pCLE shows potential as an adjunctive bronchoscopic imaging technique in the differential diagnosis of DPLD. Structured and quantitative analysis of the images is required.
背景:弥漫性肺实质疾病(DPLD)的诊断是基于临床评价、影像学和组织学。然而,需要额外的技术来提高诊断。目的和目的:基于探针的共聚焦激光内镜(pCLE)可以在支气管镜检查期间基于弹性纤维的自身荧光实时观察肺泡腔室。我们使用了pCLE (Cellvizio®,Mauna Kea Technology)。不同类型DPLD患者的肺泡模式特征。方法:在这项初步研究中,我们纳入了42名未接受治疗的患者(13名女性,年龄72.6±2.3岁),他们接受了支气管镜检查以检查DPLD。在硬支气管镜下根据HR-CT扫描在受影响的肺段获得pCLE图像,然后在同一区域进行冷冻活检。诊断是由一个多学科小组做出的。pCLE模式的描述是基于六边形肺泡模式的扭曲程度,肺泡结构的密度,实变或负载肺泡巨噬细胞(AM)的存在。评估由2名盲法研究者进行,以获得最终诊断。结果:正常肺呈典型肺泡环型。在胺碘酮肺部疾病中,负荷AM占主导地位。COP表现出特征性的局灶实变。IPF表现为明显的扭曲和破坏,NSIP表现为明显的密度增加,慢性HP表现为实变,轻度扭曲和密度。结论:pCLE可作为支气管镜鉴别诊断DPLD的辅助技术。需要对图像进行结构化和定量分析。
{"title":"Bronchoscopic Probe-Based Confocal Laser Endomicroscopy to Diagnose Diffuse Parenchymal Lung Diseases.","authors":"Edith Silbernagel,&nbsp;Elvira Stacher-Priehse,&nbsp;Julien Dinkel,&nbsp;Herbert Stepp,&nbsp;Wolfgang Gesierich,&nbsp;Michael Lindner,&nbsp;Juergen Behr,&nbsp;Frank Reichenberger","doi":"10.36141/svdld.v39i2.11280","DOIUrl":"https://doi.org/10.36141/svdld.v39i2.11280","url":null,"abstract":"Background Diagnosis of diffuse parenchymal lung disease (DPLD) is based on clinical evaluation, radiological imaging and histology. However, additional techniques are warranted to improve diagnosis. Aims and objective Probe based confocal laser endomicroscopy (pCLE) allows real time in vivo visualisation of the alveolar compartment during bronchoscopy based on autofluorescence of elastic fibres. We used pCLE (Cellvizio®, Mauna Kea Technology. Inc, Paris, France) to characterise alveolar patterns in patients with different types of DPLD. Methods In this pilot study we included 42 therapy naive patients (13 female, age 72.6 +/- 2.3 years), who underwent bronchoscopy for workup of DPLD. pCLE images were obtained during rigid bronchoscopy in affected lung segments according to HR-CT scan, followed by cryobiopsies in the identical area. Diagnoses were made by a multidisciplinary panel. The description of pCLE patterns was based on the degree of distortion of the hexagonal alveolar pattern, the density of alveolar structures, the presence of consolidations or loaded alveolar macrophages (AM). The assessment was performed by 2 investigators blinded for the final diagnosis. Results The normal lung showed a typical alveolar loop pattern. In amiodarone lung disease loaded AM were predominant. COP showed characteristic focal consolidations. IPF was characterized by significant distortion and destruction, NSIP showed significant increase in density, and chronic HP presented with consolidations, mild distortion and density. Conclusion pCLE shows potential as an adjunctive bronchoscopic imaging technique in the differential diagnosis of DPLD. Structured and quantitative analysis of the images is required.","PeriodicalId":21394,"journal":{"name":"Sarcoidosis, Vasculitis, and Diffuse Lung Diseases","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9437758/pdf/SVDLD-39-016.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40366386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
The Relationship between Serum Uric Acid Levels and Early Mortality in Chronic Obstructive Pulmonary Disease Cases during Exacerbation. 慢性阻塞性肺疾病加重期血清尿酸水平与早期死亡率的关系
IF 1.6 4区 医学 Q3 Medicine Pub Date : 2022-01-01 Epub Date: 2022-06-29 DOI: 10.36141/svdld.v39i2.12127
Gökhan Büyükbayram, Ömer Yüceer, Fatma Sema Oymak

Aim: In this study, it was aimed to compare the levels of serum uric acid and uric acid/creatinine ratios in patients with COPD during an attack or in stable COPD, and to show whether serum uric acid and uric acid/creatinine ratios are associated with early mortality in COPD patients during an acute attack.

Materials and methods: In this study, COPD acute attack (n=155) and stable COPD (n=30) patients were evaluated. The data of these patients were obtained from patient files and computer records. COPD diagnosis and severity assessment were made according to the GOLD 2006 guideline. Participants' age, gender, body mass index, pulmonary function test, arterial blood gas, uric acid, creatinine values and comorbidity information were recorded in the previously prepared Case Data Form. In 2012, when we conducted this study, gold 2006 was taken as the guideline for spirometry measurement, but spirometric measurements determined with reference values determined according to age, height and gender, and FEV1/FVC measurement <70% as diagnostic criteria in acute attack after bronchodilator were the guidelines used later, gold 2017. It is also compatible with gold2020 and gold2021 spirometry criteria.

Results: It was determined that the uric acid (p<0.001) and uric acid/creatinine (p<0.001) levels of the patients in the acute attack group were significantly higher than the levels of the patients in the stable group. The attack group was divided into two subgroups according to certain cut-off points for uric acid (>6 mg/dl for women and >7 mg/dl for men) and uric acid/creatinine ratio (median value 7.10). Since the upper limit of the uric acid value measured in the blood is 6 mg/dl in women and 7-8 mg/dl in men, the cut-off points for uric acid (>6 mg/dl for women and >7 mg/dl for men) were determined in our study. According to this categorization, it was determined that there was no statistically significant relationship between uric acid level (odds ratio 2.985 [95% confidence interval 0.61814,151]) and early mortality risk.

Conclusion: The results of this study showed that the uric acid and uric acid/creatinine levels in the attack group were higher than the levels in the stable group, but these parameters were not associated with early mortality.

目的:在本研究中,目的是比较COPD患者发作期间或稳定期的血清尿酸水平和尿酸/肌酐比值,并显示血清尿酸和尿酸/肌酐比值是否与COPD患者急性发作期间的早期死亡率相关。材料与方法:本研究对慢性阻塞性肺病急性发作期(155例)和稳定期(30例)患者进行评估。这些患者的数据来自患者档案和计算机记录。根据GOLD 2006指南进行COPD诊断和严重程度评估。参与者的年龄、性别、体重指数、肺功能检查、动脉血气、尿酸、肌酐值和合并症信息记录在事先准备的病例数据表中。我们在2012年开展本研究时,以gold 2006作为肺活量测定的指导原则,但肺活量测定采用根据年龄、身高、性别确定的参考值,FEV1/FVC测定结果:确定尿酸(女性p6 mg/dl,男性>7 mg/dl)和尿酸/肌酐比值(中位数7.10)。由于血液中尿酸值的上限女性为6毫克/分升,男性为7-8毫克/分升,因此在我们的研究中确定了尿酸的临界值(女性>6毫克/分升,男性>7毫克/分升)。根据这一分类,确定尿酸水平与早期死亡风险之间无统计学意义的关系(优势比2.985[95%可信区间0.61814,151])。结论:本研究结果显示,发作组的尿酸和尿酸/肌酐水平高于稳定组,但这些参数与早期死亡率无关。
{"title":"The Relationship between Serum Uric Acid Levels and Early Mortality in Chronic Obstructive Pulmonary Disease Cases during Exacerbation.","authors":"Gökhan Büyükbayram,&nbsp;Ömer Yüceer,&nbsp;Fatma Sema Oymak","doi":"10.36141/svdld.v39i2.12127","DOIUrl":"https://doi.org/10.36141/svdld.v39i2.12127","url":null,"abstract":"<p><strong>Aim: </strong>In this study, it was aimed to compare the levels of serum uric acid and uric acid/creatinine ratios in patients with COPD during an attack or in stable COPD, and to show whether serum uric acid and uric acid/creatinine ratios are associated with early mortality in COPD patients during an acute attack.</p><p><strong>Materials and methods: </strong>In this study, COPD acute attack (n=155) and stable COPD (n=30) patients were evaluated. The data of these patients were obtained from patient files and computer records. COPD diagnosis and severity assessment were made according to the GOLD 2006 guideline. Participants' age, gender, body mass index, pulmonary function test, arterial blood gas, uric acid, creatinine values and comorbidity information were recorded in the previously prepared Case Data Form. In 2012, when we conducted this study, gold 2006 was taken as the guideline for spirometry measurement, but spirometric measurements determined with reference values determined according to age, height and gender, and FEV1/FVC measurement <70% as diagnostic criteria in acute attack after bronchodilator were the guidelines used later, gold 2017. It is also compatible with gold2020 and gold2021 spirometry criteria.</p><p><strong>Results: </strong>It was determined that the uric acid (p<0.001) and uric acid/creatinine (p<0.001) levels of the patients in the acute attack group were significantly higher than the levels of the patients in the stable group. The attack group was divided into two subgroups according to certain cut-off points for uric acid (>6 mg/dl for women and >7 mg/dl for men) and uric acid/creatinine ratio (median value 7.10). Since the upper limit of the uric acid value measured in the blood is 6 mg/dl in women and 7-8 mg/dl in men, the cut-off points for uric acid (>6 mg/dl for women and >7 mg/dl for men) were determined in our study. According to this categorization, it was determined that there was no statistically significant relationship between uric acid level (odds ratio 2.985 [95% confidence interval 0.61814,151]) and early mortality risk.</p><p><strong>Conclusion: </strong>The results of this study showed that the uric acid and uric acid/creatinine levels in the attack group were higher than the levels in the stable group, but these parameters were not associated with early mortality.</p>","PeriodicalId":21394,"journal":{"name":"Sarcoidosis, Vasculitis, and Diffuse Lung Diseases","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9437757/pdf/SVDLD-39-014.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40366388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clarithromycin in Post COVID-19 Organizing pneumonia. 克拉霉素在COVID-19后组织性肺炎中的作用。
IF 1.6 4区 医学 Q3 Medicine Pub Date : 2022-01-01 DOI: 10.36141/svdld.v39i3.13003
Irfan Ismail Ayub, Dhanasekar Thangaswamy, Abdul Majeed Arshad, Chandrasekar Chockalingam, Lithya Kumari Sampath, Hariprasad Balakrishnan
To the Editor, An increasing number of patients are reporting with symptoms secondary to post COVID-19 pulmonary sequelae. Radiological findings in these patients include fibrotic lung disease, interstitial lung abnormalities, ground glass opacities, and organizing pneumonia (OP). Therapeutic options in these patients include steroids and anti-fibrotics. The majority of these patients have received steroid therapy for COVID-19 pneumonia, and may continue to receive it for post COVID-19 pulmonary sequelae, subjecting themselves to steroid related adverse effects. Cryptogenic organizing pneumonia (COP) responds well to steroid therapy. Alternatively, macrolide therapy has been successful in the treatment of both cryptogenic and secondary forms of OP. Compared to steroid therapy, macrolide therapy in COP is well tolerated and associated with fewer adverse events. We report two patients who were diagnosed with post COVID-19 OP who were treated successfully with clarithromycin for three months. We believe that clarithromycin offers a potential therapeutic option in post COVID-19 organizing pneumonia. Our first patient was a seventy-year-old female who presented with non productive cough and exertional dyspnea of two weeks duration. Two weeks ago, she was discharged after being hospitalized for twelve days for COVID-19 pneumonia with hypoxemia, and was treated with oxygen therapy, once daily subcutaneous low molecular weight heparin (LMWH), intravenous methylprednisolone and remdesivir. On discharge, since she continued to remain hypoxemic, she was advised to continue oral dexamethasone 6 milligram (mg) per oral (PO) (tapering doses) along with home oxygen with recommended flow of two liters per minute, with which, she maintained a peripheral saturation of 94%, for another ten days post discharge. She had no other past medical history. Clinical examination revealed a respiratory rate of 18 per minute with peripheral saturation of 95% with room air, and she had discontinued home oxygen two days ago. She had bilateral inspiratory crepitations on chest auscultation. Computed tomography (CT) of chest presently revealed bilateral peripheral interlobar septal thickening with ground glass opacities in both upper and lower lobes, along with lower lobe predominant peribronchovascular and subpleural coalescing consolidation and areas of peripheral perilobular pattern of thickening surrounding an area of normal attenuation with a solid nodule within its center, suggestive of the target sign (Figure 1). Overall, the radiology was suggestive of organizing pneumonia (OP). She was initiated on oral clarithromycin PO 500 mg twice daily for three months. She was reviewed monthly, during which her symptoms were reported to have Letter to Editor
{"title":"Clarithromycin in Post COVID-19 Organizing pneumonia.","authors":"Irfan Ismail Ayub,&nbsp;Dhanasekar Thangaswamy,&nbsp;Abdul Majeed Arshad,&nbsp;Chandrasekar Chockalingam,&nbsp;Lithya Kumari Sampath,&nbsp;Hariprasad Balakrishnan","doi":"10.36141/svdld.v39i3.13003","DOIUrl":"https://doi.org/10.36141/svdld.v39i3.13003","url":null,"abstract":"To the Editor, An increasing number of patients are reporting with symptoms secondary to post COVID-19 pulmonary sequelae. Radiological findings in these patients include fibrotic lung disease, interstitial lung abnormalities, ground glass opacities, and organizing pneumonia (OP). Therapeutic options in these patients include steroids and anti-fibrotics. The majority of these patients have received steroid therapy for COVID-19 pneumonia, and may continue to receive it for post COVID-19 pulmonary sequelae, subjecting themselves to steroid related adverse effects. Cryptogenic organizing pneumonia (COP) responds well to steroid therapy. Alternatively, macrolide therapy has been successful in the treatment of both cryptogenic and secondary forms of OP. Compared to steroid therapy, macrolide therapy in COP is well tolerated and associated with fewer adverse events. We report two patients who were diagnosed with post COVID-19 OP who were treated successfully with clarithromycin for three months. We believe that clarithromycin offers a potential therapeutic option in post COVID-19 organizing pneumonia. Our first patient was a seventy-year-old female who presented with non productive cough and exertional dyspnea of two weeks duration. Two weeks ago, she was discharged after being hospitalized for twelve days for COVID-19 pneumonia with hypoxemia, and was treated with oxygen therapy, once daily subcutaneous low molecular weight heparin (LMWH), intravenous methylprednisolone and remdesivir. On discharge, since she continued to remain hypoxemic, she was advised to continue oral dexamethasone 6 milligram (mg) per oral (PO) (tapering doses) along with home oxygen with recommended flow of two liters per minute, with which, she maintained a peripheral saturation of 94%, for another ten days post discharge. She had no other past medical history. Clinical examination revealed a respiratory rate of 18 per minute with peripheral saturation of 95% with room air, and she had discontinued home oxygen two days ago. She had bilateral inspiratory crepitations on chest auscultation. Computed tomography (CT) of chest presently revealed bilateral peripheral interlobar septal thickening with ground glass opacities in both upper and lower lobes, along with lower lobe predominant peribronchovascular and subpleural coalescing consolidation and areas of peripheral perilobular pattern of thickening surrounding an area of normal attenuation with a solid nodule within its center, suggestive of the target sign (Figure 1). Overall, the radiology was suggestive of organizing pneumonia (OP). She was initiated on oral clarithromycin PO 500 mg twice daily for three months. She was reviewed monthly, during which her symptoms were reported to have Letter to Editor","PeriodicalId":21394,"journal":{"name":"Sarcoidosis, Vasculitis, and Diffuse Lung Diseases","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/85/4b/SVDLD-39-25.PMC9766853.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10735521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
MPO-ANCA positive interstitial pneumonia: Current knowledge and future perspectives. MPO-ANCA阳性间质性肺炎:目前的认识和未来的展望。
IF 1.6 4区 医学 Q3 Medicine Pub Date : 2022-01-01 Epub Date: 2022-01-13 DOI: 10.36141/svdld.v38i4.11808
Masashi Bando, Sakae Homma, Masayoshi Harigai

Although interstitial pneumonia is an important respiratory manifestation in microscopic polyangiitis (MPA), no studies have examined the detailed pathogenesis of interstitial pneumonia during the clinical course of MPA. In addition, it is considered that MPA develops at a certain incidence rate from myeloperoxidase (MPO)- antineutrophil cytoplasmic antibody (ANCA) positive interstitial pneumonia. However, there is a lack of consensus among pulmonologist and rheumatologist regarding whether MPO-ANCA positive interstitial pneumonia, which does not accompany other organ damage related to ANCA-associated vasculitis (AAV) other than interstitial pneumonia, should be included in AAV. In this review article, the clinical questions regarding MPO-ANCA positive interstitial pneumonia have been set, and evidence to date and problems to be solved in future are outlined.

虽然间质性肺炎是显微镜下多血管炎(MPA)的重要呼吸道表现,但在MPA临床过程中,间质性肺炎的详细发病机制尚无研究。另外,认为MPA以一定的发生率发生于髓过氧化物酶(MPO)-抗中性粒细胞胞浆抗体(ANCA)阳性间质性肺炎。然而,对于MPO-ANCA阳性间质性肺炎(除了间质性肺炎外,不伴有与anca相关的血管炎(AAV)相关的其他器官损害)是否应包括在AAV中,肺病学家和风湿病学家缺乏共识。本文综述了MPO-ANCA阳性间质性肺炎的临床问题,并概述了迄今为止的证据和未来需要解决的问题。
{"title":"MPO-ANCA positive interstitial pneumonia: Current knowledge and future perspectives.","authors":"Masashi Bando,&nbsp;Sakae Homma,&nbsp;Masayoshi Harigai","doi":"10.36141/svdld.v38i4.11808","DOIUrl":"https://doi.org/10.36141/svdld.v38i4.11808","url":null,"abstract":"<p><p>Although interstitial pneumonia is an important respiratory manifestation in microscopic polyangiitis (MPA), no studies have examined the detailed pathogenesis of interstitial pneumonia during the clinical course of MPA. In addition, it is considered that MPA develops at a certain incidence rate from myeloperoxidase (MPO)- antineutrophil cytoplasmic antibody (ANCA) positive interstitial pneumonia. However, there is a lack of consensus among pulmonologist and rheumatologist regarding whether MPO-ANCA positive interstitial pneumonia, which does not accompany other organ damage related to ANCA-associated vasculitis (AAV) other than interstitial pneumonia, should be included in AAV. In this review article, the clinical questions regarding MPO-ANCA positive interstitial pneumonia have been set, and evidence to date and problems to be solved in future are outlined.</p>","PeriodicalId":21394,"journal":{"name":"Sarcoidosis, Vasculitis, and Diffuse Lung Diseases","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8a/1d/SVDLD-38-45.PMC8787377.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39762875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Echocardiographic estimate of pulmonary artery pressure in sarcoidosis patients - real world data from a multi-national study. 超声心动图估计结节病患者肺动脉压-来自多国研究的真实世界数据。
IF 1.6 4区 医学 Q3 Medicine Pub Date : 2022-01-01 Epub Date: 2022-01-13 DOI: 10.36141/svdld.v38i4.11376
Marloes P Huitema, Marco C Post, Jan C Grutters, Athol U Wells, Vasilis Kouranos, Oksana A Shlobin, Steven D Nathan, Daniel A Culver, Joseph Barney, Rohit Gupta, Eva Carmona, Esam H Alhamad, Mary B Scholand, Marlies Wijsenbeek, Sivagini Ganesh, Elyse E Lower, Peter J Engel, Robert P Baughman

Introduction: Echocardiographic measurement of the right ventricular systolic pressure (RVSP) is commonly used for estimating systolic pulmonary artery pressure (PASP) measured during right heart catheterization (RHC) in patients suspected for pulmonary hypertension (PH). Generally, there seems to be a strong correlation. However, this has been reported as less robust in sarcoidosis. We aim to investigate the correlation between RVSP and RHC measurements using real world data and analyzed factors influencing the relationship between RVSP and PASP in sarcoidosis.

Methods & results: Data of patients with and without sarcoidosis associated PH who had both a measurable echocardiographic RVSP and invasive PASP were collected from the RESAPH registry, PULSAR study and Cincinnati Sarcoidosis Clinic database (n=173, 60.1% female, mean age 56.0±9.5 years). Among them, 124 had PH confirmed by RHC. There was a strong correlation between RVSP and PASP (r=0.640). This correlation was significant in both male and female, white or non-white, forced vital capacity (FVC) >60%, and presence of fibrosis (p<0.001). However, it was less robust in patients with FVC of 50% or less. RVSP was considered inaccurate if the difference with PASP was > 10mmHg. Inaccurate echocardiographic estimation of the invasive PASP occurred in 50.8%, with overestimation mostly in patients without PH, and underestimation in patients with severe PH. An RVSP>50mmHg was associated with worse survival.

Conclusions: In this real world multicenter cohort of sarcoidosis patients, we found a significant correlation between RVSP as determined by echocardiography and invasive PASP. Over- or underestimation of PASP occurred frequently. Therefore, echocardiographic RVSP measurement alone to screen for PH in sarcoidosis should be used with caution.

超声心动图测量右心室收缩压(RVSP)通常用于估计疑似肺动脉高压(PH)患者右心导管(RHC)期间测量的肺动脉收缩压(PASP)。总的来说,似乎有很强的相关性。然而,据报道,这在结节病中不太强健。我们的目的是利用真实世界的数据来研究RVSP和RHC测量之间的相关性,并分析影响结节病中RVSP和PASP关系的因素。方法与结果:从RESAPH登记、PULSAR研究和辛辛那提结节病临床数据库中收集具有可测量的超声心动图RVSP和侵袭性PASP的伴有和不伴有结节病相关PH的患者的数据(n=173,女性60.1%,平均年龄56.0±9.5岁)。其中RHC确认PH 124例。RVSP与PASP有很强的相关性(r=0.640)。这种相关性在男性和女性、白人或非白人、用力肺活量(FVC) >60%和纤维化存在(p 10mmHg)中都很显著。有创性PASP超声心动图估计不准确的发生率为50.8%,无PH患者大多高估,严重PH患者低估。RVSP>50mmHg与较差的生存相关。结论:在这个真实世界的多中心结节病患者队列中,我们发现超声心动图检测的RVSP与有创性PASP之间存在显著相关性。PASP常被高估或低估。因此,超声心动图RVSP测量单独筛选PH结节病应谨慎使用。
{"title":"Echocardiographic estimate of pulmonary artery pressure in sarcoidosis patients - real world data from a multi-national study.","authors":"Marloes P Huitema,&nbsp;Marco C Post,&nbsp;Jan C Grutters,&nbsp;Athol U Wells,&nbsp;Vasilis Kouranos,&nbsp;Oksana A Shlobin,&nbsp;Steven D Nathan,&nbsp;Daniel A Culver,&nbsp;Joseph Barney,&nbsp;Rohit Gupta,&nbsp;Eva Carmona,&nbsp;Esam H Alhamad,&nbsp;Mary B Scholand,&nbsp;Marlies Wijsenbeek,&nbsp;Sivagini Ganesh,&nbsp;Elyse E Lower,&nbsp;Peter J Engel,&nbsp;Robert P Baughman","doi":"10.36141/svdld.v38i4.11376","DOIUrl":"https://doi.org/10.36141/svdld.v38i4.11376","url":null,"abstract":"<p><strong>Introduction: </strong>Echocardiographic measurement of the right ventricular systolic pressure (RVSP) is commonly used for estimating systolic pulmonary artery pressure (PASP) measured during right heart catheterization (RHC) in patients suspected for pulmonary hypertension (PH). Generally, there seems to be a strong correlation. However, this has been reported as less robust in sarcoidosis. We aim to investigate the correlation between RVSP and RHC measurements using real world data and analyzed factors influencing the relationship between RVSP and PASP in sarcoidosis.</p><p><strong>Methods & results: </strong>Data of patients with and without sarcoidosis associated PH who had both a measurable echocardiographic RVSP and invasive PASP were collected from the RESAPH registry, PULSAR study and Cincinnati Sarcoidosis Clinic database (n=173, 60.1% female, mean age 56.0±9.5 years). Among them, 124 had PH confirmed by RHC. There was a strong correlation between RVSP and PASP (r=0.640). This correlation was significant in both male and female, white or non-white, forced vital capacity (FVC) >60%, and presence of fibrosis (p<0.001). However, it was less robust in patients with FVC of 50% or less. RVSP was considered inaccurate if the difference with PASP was > 10mmHg. Inaccurate echocardiographic estimation of the invasive PASP occurred in 50.8%, with overestimation mostly in patients without PH, and underestimation in patients with severe PH. An RVSP>50mmHg was associated with worse survival.</p><p><strong>Conclusions: </strong>In this real world multicenter cohort of sarcoidosis patients, we found a significant correlation between RVSP as determined by echocardiography and invasive PASP. Over- or underestimation of PASP occurred frequently. Therefore, echocardiographic RVSP measurement alone to screen for PH in sarcoidosis should be used with caution.</p>","PeriodicalId":21394,"journal":{"name":"Sarcoidosis, Vasculitis, and Diffuse Lung Diseases","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ba/4f/SVDLD-38-32.PMC8787381.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39747943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 7
How We Do It: Whole Lung Lavage. 治疗方法:全肺灌洗。
IF 1.6 4区 医学 Q3 Medicine Pub Date : 2022-01-01 Epub Date: 2022-06-29 DOI: 10.36141/svdld.v39i2.12884
Deepa Shrestha, Sahajal Dhooria, Ganesh Kumar Munirathinam, Inderpaul Singh Sehgal, Kuruswamy Thurai Prasad, Babu Ram, Harkant Singh, Ashutosh N Aggarwal, Goverdhan D Puri, Valliappan Muthu, Ritesh Agarwal

Pulmonary alveolar proteinosis (PAP) is a rare pulmonary disorder characterized by the accumulation of surfactant in the alveolar spaces resulting in hypoxemic respiratory failure. Whole lung lavage (WLL), the preferred treatment for PAP, physically removes the lipoproteinaceous material from the alveolar spaces. Since its initial description in 1963, the WLL procedure has undergone various modifications. However, the procedure has not been standardized yet. After securing a double lumen endotracheal tube, we perform WLL under general anesthesia. One lung is ventilated, while the other is lavaged using one-liter aliquots of pre-warmed saline. We use gravity-assisted drainage of the lavaged lung after each cycle till the milky white and opaque fluid becomes clear (usually 15-20 cycles). Herein, we describe the step-by-step procedure, precautions, and monitoring of WLL. We also provide videos demonstrating one-lung ventilation and bronchoscopic confirmation of lung isolation.

肺泡蛋白沉积症(PAP)是一种罕见的肺部疾病,其特征是表面活性剂在肺泡间隙积聚,导致低氧性呼吸衰竭。全肺灌洗(WLL)是PAP的首选治疗方法,可物理清除肺泡间隙中的脂蛋白物质。自1963年首次提出WLL程序以来,该程序经历了多次修改。然而,这一程序尚未标准化。在固定双腔气管内管后,我们在全身麻醉下进行WLL。一只肺进行通气,另一只肺用一升等量的预热盐水灌洗。我们在每个周期后使用重力辅助引流洗肺,直到乳白色和不透明的液体变得清晰(通常为15-20周期)。在这里,我们描述了WLL的一步一步的程序,注意事项和监测。我们还提供视频演示单肺通气和支气管镜确认肺隔离。
{"title":"How We Do It: Whole Lung Lavage.","authors":"Deepa Shrestha,&nbsp;Sahajal Dhooria,&nbsp;Ganesh Kumar Munirathinam,&nbsp;Inderpaul Singh Sehgal,&nbsp;Kuruswamy Thurai Prasad,&nbsp;Babu Ram,&nbsp;Harkant Singh,&nbsp;Ashutosh N Aggarwal,&nbsp;Goverdhan D Puri,&nbsp;Valliappan Muthu,&nbsp;Ritesh Agarwal","doi":"10.36141/svdld.v39i2.12884","DOIUrl":"https://doi.org/10.36141/svdld.v39i2.12884","url":null,"abstract":"<p><p>Pulmonary alveolar proteinosis (PAP) is a rare pulmonary disorder characterized by the accumulation of surfactant in the alveolar spaces resulting in hypoxemic respiratory failure. Whole lung lavage (WLL), the preferred treatment for PAP, physically removes the lipoproteinaceous material from the alveolar spaces. Since its initial description in 1963, the WLL procedure has undergone various modifications. However, the procedure has not been standardized yet. After securing a double lumen endotracheal tube, we perform WLL under general anesthesia. One lung is ventilated, while the other is lavaged using one-liter aliquots of pre-warmed saline. We use gravity-assisted drainage of the lavaged lung after each cycle till the milky white and opaque fluid becomes clear (usually 15-20 cycles). Herein, we describe the step-by-step procedure, precautions, and monitoring of WLL. We also provide videos demonstrating one-lung ventilation and bronchoscopic confirmation of lung isolation.</p>","PeriodicalId":21394,"journal":{"name":"Sarcoidosis, Vasculitis, and Diffuse Lung Diseases","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9437756/pdf/SVDLD-39-017.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40366389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Imaging Findings of Fibrosis in Pulmonary Sarcoidosis. 肺结节病纤维化的影像学表现。
IF 1.6 4区 医学 Q3 Medicine Pub Date : 2022-01-01 Epub Date: 2022-06-29 DOI: 10.36141/svdld.v39i2.12995
Michiru Sawahata, Tetsuo Yamaguchi

Background: In pulmonary sarcoidosis, respiratory tract lesions almost always appear, and residual lung shadows require treatment in about 20% of cases. Pulmonary fibrosis is among the three leading causes of death. Treatment strategies are urgently needed to inhibit the progression of pulmonary fibrosis by combining antifibrotic drugs and immunosuppressive drugs such as corticosteroids. Establishing consensus on the process of pulmonary fibrosis progression is important for determining the most effective treatment.

Our review: Among more than 2500 cases of sarcoidosis treated at our hospital, cases that led to chronic respiratory failure were analyzed for CT findings of pulmonary fibrosis. Early in sarcoidosis, granulomatous lesions appeared along the bronchovascular bundle. As pulmonary fibrosis progressed, a central consolidation developed on the central side in the direction of lymph flow, a peripheral consolidation developed on the pleural side, and a central-peripheral band developed connecting the two. Infiltrative or wedge-shaped shadows sometimes formed in the immediate subpleural area, appearing as a pleuroparenchymal fibroelastosis-like lesion. Traction bronchiectasis may form cysts at the periphery or may congregate to form a honeycomb lung-like structure. Combination of these lesions led to shrinkage of the upper lobe. Patients with multiple peripheral cysts/bullae had a unique disease course characterized by wheezing and concomitant pulmonary hypertension and pulmonary aspergillosis.

Conclusion: Further understanding of the process of pulmonary fibrosis progression is needed. Summarizing imaging findings and understanding their contribution to respiratory impairment will contribute to comprehensively evaluating the stages of pulmonary fibrosis progression and establishing an optimal treatment strategy.

背景:肺结节病几乎总是出现呼吸道病变,约20%的病例需要治疗残余肺影。肺纤维化是三大死亡原因之一。迫切需要联合抗纤维化药物和免疫抑制药物(如皮质类固醇)抑制肺纤维化进展的治疗策略。建立关于肺纤维化进展过程的共识对于确定最有效的治疗方法非常重要。我们的回顾:在我院治疗的2500多例结节病中,我们分析了导致慢性呼吸衰竭的病例的肺纤维化的CT表现。结节病早期,沿支气管维管束出现肉芽肿性病变。随着肺纤维化的进展,在淋巴流动方向的中央侧出现中央实变,在胸膜侧出现外周实变,并形成连接两者的中央-外周带。浸润性或楔形阴影有时在紧邻的胸膜下区形成,表现为胸膜实质纤维弹性样病变。牵引性支气管扩张可在周围形成囊肿或聚集形成蜂窝状肺样结构。这些病变的合并导致上肺叶萎缩。多发性外周囊肿/大疱患者有一个独特的病程,其特征是喘息并伴有肺动脉高压和肺曲霉病。结论:需要进一步了解肺纤维化的进展过程。总结影像学表现并了解其对呼吸损伤的影响将有助于全面评估肺纤维化进展的阶段并建立最佳治疗策略。
{"title":"Imaging Findings of Fibrosis in Pulmonary Sarcoidosis.","authors":"Michiru Sawahata,&nbsp;Tetsuo Yamaguchi","doi":"10.36141/svdld.v39i2.12995","DOIUrl":"https://doi.org/10.36141/svdld.v39i2.12995","url":null,"abstract":"<p><strong>Background: </strong>In pulmonary sarcoidosis, respiratory tract lesions almost always appear, and residual lung shadows require treatment in about 20% of cases. Pulmonary fibrosis is among the three leading causes of death. Treatment strategies are urgently needed to inhibit the progression of pulmonary fibrosis by combining antifibrotic drugs and immunosuppressive drugs such as corticosteroids. Establishing consensus on the process of pulmonary fibrosis progression is important for determining the most effective treatment.</p><p><strong>Our review: </strong>Among more than 2500 cases of sarcoidosis treated at our hospital, cases that led to chronic respiratory failure were analyzed for CT findings of pulmonary fibrosis. Early in sarcoidosis, granulomatous lesions appeared along the bronchovascular bundle. As pulmonary fibrosis progressed, a central consolidation developed on the central side in the direction of lymph flow, a peripheral consolidation developed on the pleural side, and a central-peripheral band developed connecting the two. Infiltrative or wedge-shaped shadows sometimes formed in the immediate subpleural area, appearing as a pleuroparenchymal fibroelastosis-like lesion. Traction bronchiectasis may form cysts at the periphery or may congregate to form a honeycomb lung-like structure. Combination of these lesions led to shrinkage of the upper lobe. Patients with multiple peripheral cysts/bullae had a unique disease course characterized by wheezing and concomitant pulmonary hypertension and pulmonary aspergillosis.</p><p><strong>Conclusion: </strong>Further understanding of the process of pulmonary fibrosis progression is needed. Summarizing imaging findings and understanding their contribution to respiratory impairment will contribute to comprehensively evaluating the stages of pulmonary fibrosis progression and establishing an optimal treatment strategy.</p>","PeriodicalId":21394,"journal":{"name":"Sarcoidosis, Vasculitis, and Diffuse Lung Diseases","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9437761/pdf/SVDLD-39-018.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40366391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
An unusual case of takayasu arteritis presenting as acute myocardial infarction and ischaemic stroke. 以急性心肌梗死及缺血性脑卒中为表现的罕见高须动脉炎病例。
IF 1.6 4区 医学 Q3 Medicine Pub Date : 2022-01-01 DOI: 10.36141/svdld.v39i3.12688
Sonja Golubović, Mia Manojlović, Tatjana Ilić, Filip Samardzić, Biljana Vučković, Dragana Tomić-Naglić, Ivana Bajkin, Slađana Pejaković

Introduction: Takayasu's arteritis (TA) is well-known yet rare disorder, defined as a chronic large vessel vasculitis mainly involving the aorta and its major branches. We present a complex case of a 51-year-old female patient who first presented with acute myocardial infarction as an initial manifestation of Takayasu arteritis, and later with an acute onset of ischemic stroke.

Case report: We present a case of 51-year-old female patient who was admitted at the Clinic of Nephrology and Clinical Immunology. During hospitalization, a sudden onset of intense chest pain occurred, followed by a development of heart failure to the level of cardiogenic shock. Electrocardiography showed signs of ST-elevated myocardial infarction (STEMI) of the anterior wall, and an increase in cardiospecific enzymes. CT angiography indicated an occlusion of the left common carotid artery (ACC), subclavian and axillary arteries as well as a penetrating aortic ulcer localized infrarenal. In the further course of treatment, left-sided weakness of the body was registered. Head CT scan showed an acute ischemic lesion high parietal on the right, as well as a chronic ischemic lesion on the front right. Doppler ultrasonography of carotid and vertebral arteries registered left occlusion, right ACC/external carotid artery (ACE) stenosis with suspected "macaroni sign". Final diagnosis of Takayasu arteritis was established and corticosteroids were included in the therapy (primarily in pulse doses) with the first pulse of cyclophosphamide of 1000mg.

Conclusion: This disease should be considered in female patients who present with chronic inflammation and acute coronary syndrome.

简介:Takayasu’s arteritis (TA)是一种众所周知但罕见的疾病,定义为主要累及主动脉及其主要分支的慢性大血管炎。我们提出一个复杂的情况下,51岁的女性患者谁首先提出了急性心肌梗死作为高松动脉炎的初始表现,后来急性发作缺血性中风。病例报告:我们报告了一例51岁的女性患者,她住在肾内科和临床免疫学诊所。住院期间,突然出现剧烈胸痛,随后发展为心力衰竭,直至心源性休克。心电图显示前壁st段升高的心肌梗死(STEMI)的迹象,心脏特异性酶的增加。CT血管造影显示左侧颈总动脉(ACC)、锁骨下动脉和腋窝动脉闭塞,并发现穿透性主动脉溃疡,位于肾下。在进一步的治疗过程中,左侧身体虚弱。头部CT扫描显示右侧高顶叶急性缺血性病变,右前方慢性缺血性病变。颈动脉及椎动脉多普勒超声示左侧闭塞,右侧ACC/颈外动脉(ACE)狭窄,疑似“通心粉征”。最终诊断为Takayasu动脉炎,并将皮质类固醇纳入治疗(主要是脉冲剂量),第一次脉冲环磷酰胺为1000mg。结论:慢性炎症伴急性冠状动脉综合征的女性患者应考虑本病。
{"title":"An unusual case of takayasu arteritis presenting as acute myocardial infarction and ischaemic stroke.","authors":"Sonja Golubović,&nbsp;Mia Manojlović,&nbsp;Tatjana Ilić,&nbsp;Filip Samardzić,&nbsp;Biljana Vučković,&nbsp;Dragana Tomić-Naglić,&nbsp;Ivana Bajkin,&nbsp;Slađana Pejaković","doi":"10.36141/svdld.v39i3.12688","DOIUrl":"https://doi.org/10.36141/svdld.v39i3.12688","url":null,"abstract":"<p><strong>Introduction: </strong>Takayasu's arteritis (TA) is well-known yet rare disorder, defined as a chronic large vessel vasculitis mainly involving the aorta and its major branches. We present a complex case of a 51-year-old female patient who first presented with acute myocardial infarction as an initial manifestation of Takayasu arteritis, and later with an acute onset of ischemic stroke.</p><p><strong>Case report: </strong>We present a case of 51-year-old female patient who was admitted at the Clinic of Nephrology and Clinical Immunology. During hospitalization, a sudden onset of intense chest pain occurred, followed by a development of heart failure to the level of cardiogenic shock. Electrocardiography showed signs of ST-elevated myocardial infarction (STEMI) of the anterior wall, and an increase in cardiospecific enzymes. CT angiography indicated an occlusion of the left common carotid artery (ACC), subclavian and axillary arteries as well as a penetrating aortic ulcer localized infrarenal. In the further course of treatment, left-sided weakness of the body was registered. Head CT scan showed an acute ischemic lesion high parietal on the right, as well as a chronic ischemic lesion on the front right. Doppler ultrasonography of carotid and vertebral arteries registered left occlusion, right ACC/external carotid artery (ACE) stenosis with suspected \"macaroni sign\". Final diagnosis of Takayasu arteritis was established and corticosteroids were included in the therapy (primarily in pulse doses) with the first pulse of cyclophosphamide of 1000mg.</p><p><strong>Conclusion: </strong>This disease should be considered in female patients who present with chronic inflammation and acute coronary syndrome.</p>","PeriodicalId":21394,"journal":{"name":"Sarcoidosis, Vasculitis, and Diffuse Lung Diseases","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/7a/d6/SVDLD-39-27.PMC9766845.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10739101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Atherogenic Indices Can Predict Atherosclerosis in Patients with Sarcoidosis. 动脉粥样硬化指标可预测结节病患者动脉粥样硬化。
IF 1.6 4区 医学 Q3 Medicine Pub Date : 2022-01-01 Epub Date: 2022-01-13 DOI: 10.36141/svdld.v38i4.11049
Okan Selendili, Ersin Günay, Emre Kaçar, Şule Çilekar, Gürhan Öz, Ahmet Dumanli, Sibel Günay

Background: Sarcoidosis, a multisystemic disease of unknown etiology, is characterized by non-caseating granulomatous inflammation. This study aimed to investigate the efficiency of atherogenic indices and ultrasonographic evaluation of carotid artery on predicting atherosclerosis in patients with sarcoidosis.

Methods: The study included 44 subjects followed with diagnosis of sarcoidosis and 53 age and gender matched healthy subjects as controls. Laboratory findings, pulmonary function tests and carotid artery ultrasonography of all participants were evaluated.

Results: Of the participants with sarcoidosis 70.5% was female and the mean age was 35.36±7.18 years, while 64.2% of the control group were female and the mean age was 33.58±8.13 years (P=0.511 and P=0.191, respectively). High-density-lipoprotein cholesterol level in the sarcoidosis group was significantly lower than that of the control group (P=0.017), while other cholesterol levels were higher than those of the controls (P<0.05). Intima-media thickness (IMT) and peak systolic velocity (PSV) of carotid artery were higher in patients with sarcoidosis (P<0.001 and P=0.009, respectively). Atherogenic indices (Atherogenic Index (AI), Atherogenic Coefficient (AC) and Cardiogenic Risk Ratio (CRR)) were higher in sarcoidosis group compared to the controls (P<0.001, for all parameters). IMT was positively correlated with PSV, AI, AC, and CRR. A positive correlation between PSV and atherogenic indices was also detected.

Conclusions: Sarcoidosis may be a predisposing factor for atherosclerosis. Atherogenic indices, IMT of carotid artery and PSV might be considered predictors for atherosclerosis and cardiovascular diseases in asymptomatic sarcoidosis patients.

背景:结节病是一种病因不明的多系统疾病,以非干酪化肉芽肿性炎症为特征。本研究旨在探讨颈动脉粥样硬化指标及超声评价对结节病患者动脉粥样硬化的预测作用。方法:选取44例结节病诊断者和53例年龄、性别匹配的健康人作为对照。对所有参与者的实验室检查结果、肺功能检查和颈动脉超声检查进行评估。结果:结节病患者中女性占70.5%,平均年龄为35.36±7.18岁;对照组中女性占64.2%,平均年龄为33.58±8.13岁(P=0.511、P=0.191)。结节病组高密度脂蛋白胆固醇水平显著低于对照组(P=0.017),其他胆固醇水平均高于对照组(P结论:结节病可能是动脉粥样硬化的易感因素之一)。动脉粥样硬化指标、颈动脉IMT和PSV可作为无症状结节病患者动脉粥样硬化和心血管疾病的预测指标。
{"title":"Atherogenic Indices Can Predict Atherosclerosis in Patients with Sarcoidosis.","authors":"Okan Selendili,&nbsp;Ersin Günay,&nbsp;Emre Kaçar,&nbsp;Şule Çilekar,&nbsp;Gürhan Öz,&nbsp;Ahmet Dumanli,&nbsp;Sibel Günay","doi":"10.36141/svdld.v38i4.11049","DOIUrl":"https://doi.org/10.36141/svdld.v38i4.11049","url":null,"abstract":"<p><strong>Background: </strong>Sarcoidosis, a multisystemic disease of unknown etiology, is characterized by non-caseating granulomatous inflammation. This study aimed to investigate the efficiency of atherogenic indices and ultrasonographic evaluation of carotid artery on predicting atherosclerosis in patients with sarcoidosis.</p><p><strong>Methods: </strong>The study included 44 subjects followed with diagnosis of sarcoidosis and 53 age and gender matched healthy subjects as controls. Laboratory findings, pulmonary function tests and carotid artery ultrasonography of all participants were evaluated.</p><p><strong>Results: </strong>Of the participants with sarcoidosis 70.5% was female and the mean age was 35.36±7.18 years, while 64.2% of the control group were female and the mean age was 33.58±8.13 years (P=0.511 and P=0.191, respectively). High-density-lipoprotein cholesterol level in the sarcoidosis group was significantly lower than that of the control group (P=0.017), while other cholesterol levels were higher than those of the controls (P<0.05). Intima-media thickness (IMT) and peak systolic velocity (PSV) of carotid artery were higher in patients with sarcoidosis (P<0.001 and P=0.009, respectively). Atherogenic indices (Atherogenic Index (AI), Atherogenic Coefficient (AC) and Cardiogenic Risk Ratio (CRR)) were higher in sarcoidosis group compared to the controls (P<0.001, for all parameters). IMT was positively correlated with PSV, AI, AC, and CRR. A positive correlation between PSV and atherogenic indices was also detected.</p><p><strong>Conclusions: </strong>Sarcoidosis may be a predisposing factor for atherosclerosis. Atherogenic indices, IMT of carotid artery and PSV might be considered predictors for atherosclerosis and cardiovascular diseases in asymptomatic sarcoidosis patients.</p>","PeriodicalId":21394,"journal":{"name":"Sarcoidosis, Vasculitis, and Diffuse Lung Diseases","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ad/3f/SVDLD-38-41.PMC8787378.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39747947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
期刊
Sarcoidosis, Vasculitis, and Diffuse Lung Diseases
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1